New Delhi : Drug firm Cipla said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection.
“United States Food and Drug Administration (USFDA) recently concluded audit of our three manufacturing facilities in Goa and has issued four observations across these three facilities,” Cipla said in a filing to BSE.
These observations were primarily procedural in nature and the company has already responded to the same, it added.
The company, however, did not provide any details of the observations.
“We continue to operate our facilities with a high level of compliance and control,” Cipla said.
The stock was trading at Rs 581.55 in the afternoon trade on BSE, down 3.22 per cent from its previous close.
Latest posts by savita thakur (see all)
- 2000 medicines to become up to 90 percent cheaper: Nadda - November 7, 2016
- Drugmakers under fire for possible US price fixing - November 7, 2016
- Pharma cos see huge sell off: Sun Pharma, Dr Reddys hit hard - November 7, 2016